Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | PLK1 | P53350 | 2/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 3/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467697 | 1.00 | DPP7 (0.40) | DPP7PLK1GNAI3GNAO1GNAI1 | |
| SCHEMBL23451329 | 1.00 | DPP7 (0.40) | DPP7PLK1GNAI3GNAO1GNAI1 | |
| SCHEMBL29467645 | 0.87 | PLK1 (0.45) | DPP7PLK1GLP1RTLR2TSHR | |
| SCHEMBL30407180 | 0.82 | TDP1 (0.39) | DPP7GNAI3GNAO1GNAI1GLP1R | |
| SCHEMBL30410601 | 0.82 | GLP1R (0.44) | GLP1RTLR2 | |
| SCHEMBL31756841 | 0.81 | PLK1 (0.42) | DPP7PLK1TLR2 | |
| SCHEMBL29131983 | 0.81 | PLK1 (0.42) | DPP7PLK1TLR2 | |
| SCHEMBL26232048 | 0.81 | PLK1 (0.42) | DPP7PLK1TLR2 | |
| SCHEMBL30407618 | 0.81 | TDP1 (0.38) | DPP7GNAI3GNAO1GNAI1GLP1R | |
| SCHEMBL30407749 | 0.81 | TDP1 (0.38) | DPP7GNAI3GNAO1GNAI1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | PBDC1, BRD2, CD79B | DPP7 2162/4885PLK1 256/4885GNAI3 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.